Sullivan, Ryan J.
Weber, Jeffrey S.
Article History
Accepted: 16 June 2021
First Online: 27 July 2021
Competing interests
: J.S.W. is a consultant for Merck, Genentech, AstraZeneca, Pfizer, Regeneron, GSK, Alkermes, Novartis, Celldex, Incyte and EMD Serono. He is a member of the advisory board for BMS, and holds equity in CytoMx, Biond, Neximmune and Immunimax. He is also part of the scientific advisory boards for Celldex, CytoMx, Incyte, Biond, Neximmune and Sellas. J.S.W.’s laboratory has received research support from BMS, Merck, GSK, Novartis, Moderna and AstraZeneca. Moffitt Cancer Center filed a patent on an ipilimumab biomarker and a TIL growth method, in which J.S.W. has been named, as well as in a PD1 biomarker patent by Biodesix. R.J.S. declares no competing interests.